Format

Send to

Choose Destination
Oncotarget. 2015 May 20;6(14):12763-73.

The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers.

Author information

1
Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland.
2
Cancer Science Institute of Singapore, National University of Singapore, Singapore.
3
Department of Medical Oncology, National Cancer Centre Singapore, Singapore.
4
Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
5
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
6
Curtin Health Innovation Research Institute, Biosciences Research Precinct, School of Biomedical Sciences, Faculty of Health Sciences, Curtin University, Western Australia, Australia.
7
Department of Biological Sciences, University of North Texas, Denton, Texas, United States of America.
8
National University of Singapore Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore.

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the Western world. It is becoming increasingly clear that CRC is a diverse disease, as exemplified by the identification of subgroups of CRC tumours that are driven by distinct biology. Recently, a number of studies have begun to define panels of diagnostically relevant markers to align patients into individual subgroups in an attempt to give information on prognosis and treatment response. We examined the immunohistochemical expression profile of 18 markers, each representing a putative role in cancer development, in 493 primary colorectal carcinomas using tissue microarrays. Through unsupervised clustering in stage II cancers, we identified two cluster groups that are broadly defined by inflammatory or immune-related factors (CD3, CD8, COX-2 and FOXP3) and stem-like factors (CD44, LGR5, SOX2, OCT4). The expression of the stem-like group markers was associated with a significantly worse prognosis compared to cases with lower expression. In addition, patients classified in the stem-like subgroup displayed a trend towards a benefit from adjuvant treatment. The biologically relevant and poor prognostic stem-like group could also be identified in early stage I cancers, suggesting a potential opportunity for the identification of aggressive tumors at a very early stage of the disease.

KEYWORDS:

biomarkers; cancer stem-cell; carcinoma; colorectal; immunohistochemistry

PMID:
25906747
PMCID:
PMC4494972
DOI:
10.18632/oncotarget.3497
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center